Predict your next investment

AFT Pharmaceuticals company logo
HEALTHCARE | Pharmaceuticals / Drugs
aftpharm.com

See what CB Insights has to offer

Founded Year

1997

About AFT Pharmaceuticals

AFT Pharmaceuticals develops, licenses, and sells pharmaceutical products.

AFT Pharmaceuticals Headquarter Location

Level 1 129 Hurstmere Road

Auckland, 0622,

New Zealand

+64 0800423823

Latest AFT Pharmaceuticals News

03:00 ET Novaliq Receives EU Quality Management Certificate According To New Medical Device Regulation (MDR)

Oct 12, 2021

News provided by Share this article Share this article HEIDELBERG, Germany, Oct. 12, 2021 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced that it has implemented and applies a quality management system in accordance with Annex IX, Chapter I of the EU Medical Device Regulation (MDR), for conformity assessment of its medical devices NovaTears®, NovaTears®+Omega-3 and EvoTears™ OMEGA. Medical devices are products or equipment intended generally for a medical use. On 26 May, 2021, the Medical Device Directive (MDD) has been replaced by the new Medical Device Regulation (MDR). MDR is designed to be an improved version of MDD, increasing in particular the standards on quality and safety measures. Medical devices in the EU have to undergo a conformity assessment to demonstrate that they meet legal requirements to ensure they are safe and perform as intended. Manufacturers can place a CE (Conformité Européenne) mark on a medical device once it has passed a conformity assessment. The changes introduced in the MDR affect a variety of aspects in the CE marking process. Some of these processes include device classification, technical file documentation, new responsibilities for the European Medicines Agency (EMA) and post-market activities. The goal of this is to increase the qualitative standards of medical devices within the EU, ensuring improved levels of safety whilst encouraging innovation. An audit by mdc medical device certification GmbH has proven that Novaliq's quality management system fullfils the respective requirements and a conformity certificate has been issued in September 2021. "We are very pleased with our decision to implement MDR already in 2021. The safety and quality of our products is a priority to us. Therefore we always seek to implement the highest standards for the benefit of patients, customers and partners ," said Christian Roesky, Ph.D., Managing Director and CEO, Novaliq. About Novaliq's medical device eye care products NovaTears® is the first water-free and preservation-free eye drop for the treatment of dry eye. The product is CE certified since 2014 and successfully commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears™ by Ursapharm. As the first-of-its kind, NovaTears® offers a new mode of action by acting as a lubricating lipid layer stabilizer and evaporative barrier for improving tear film stability and quality. NovaTears® is clinically validated by demonstrating improvement in signs and symptoms in evaporative dry eye disease (DED) and dry eye associated with meibomian gland dysfunction (MGD) patients.1;2 With millions of NovaTears®/EvoTears™ units sold, the technology is proven to be safe and well accepted. NovaTears®+Omega-3 is the first vegan eye drop formulation combining perfluorohexyloctane, the sole ingredient of NovaTears®, with omega-3 fatty acid esters which are a natural component of the tear film and potentially important for evaporation and oxidative stress resistance. The product is free of antimicrobial preservatives and does not contain phosphate. NovaTears®+Omega-3 eye drops provide an easy and unique way to supply omega-3 right to the place of application for patients concerned about their eyes. The product received CE-marking in October 2017 and is commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears™ OMEGA by Ursapharm. About Novaliq Novaliq is a biopharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology. Novaliq offers an industry-leading portfolio addressing today's unmet medical needs of millions of patients with eye diseases. Novaliq GmbH is headquartered in Heidelberg, Germany and Novaliq Inc. has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech holding GmbH & Co. KG, an active investor in Life and Health Sciences companies. More on www.novaliq.com . References Steven P, Scherer D, Krösser S, et al. Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease--A Prospective, Multicenter Noninterventional Study. J Ocul Pharmacol Ther. 2015;31(8):498-503. Steven P, Augustin AJ, Geerling G, et al. Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease. J Ocul Pharmacol Ther. 2017;33(9):678-685. ### © 2021 Novaliq GmbH, Heidelberg, Germany. Novaliq Media Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

AFT Pharmaceuticals Patents

AFT Pharmaceuticals has filed 7 patents.

The 3 most popular patent topics include:

  • Analgesics
  • Hepatotoxins
  • Phenols
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/5/2013

1/14/2020

Analgesics, Hepatotoxins, Morphinans, Phenols, Opioids

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/5/2013

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

1/14/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Analgesics, Hepatotoxins, Morphinans, Phenols, Opioids

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

AFT Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

AFT Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.